Role of epidermal growth factor inhibition in experimental pulmonary hypertension. - Wikidata - awgldk - TriplyDB

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

http://www.wikidata.org/entity/Q43256381

about

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2 Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats.Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive d Effects of chrysin (5,7-dihydroxyflavone) on vascular remodeling in hypoxia-induced pulmonary hypertension in rats Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β.Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK.A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension.The H2S-generating enzymes cystathionine β-synthase and cystathionine γ-lyase play a role in vascular development during normal lung alveolarization.IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation.Trigeminal nerve injury ErbB3/ErbB2 promotes mechanical hypersensitivity.Signal transduction in the development of pulmonary arterial hypertension A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.Inhalation of the BK(Ca)-opener NS1619 attenuates right ventricular pressure and improves oxygenation in the rat monocrotaline model of pulmonary hypertension.Mechanisms of disease: pulmonary arterial hypertension.Update on pulmonary vascular diseases 2010.Imatinib mesylate for the treatment of pulmonary arterial hypertension.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension.Novel and emerging therapies for pulmonary hypertension.Endothelial nanomedicine for the treatment of pulmonary disease.Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.Novel investigational therapies for treating pulmonary arterial hypertension.Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL).The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies.Csk/Src/EGFR signaling regulates migration of myofibroblasts and alveolarization.Fluorofenidone attenuates vascular remodeling in hypoxia-induced pulmonary hypertension of rats.Altered Redox Balance in the Development of Chronic Hypoxia-induced Pulmonary Hypertension.Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension.Finally, Progress in Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction.Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension.Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases.Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease.Hypoxic-induction of arginase II requires EGF-mediated EGFR activation in human pulmonary microvascular endothelial cells.Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension

P2860

Q21284417-754F5156-4F45-44DE-B389-A9DC47D02067 Q28582157-F9B70806-8992-4F38-8382-6611F042019E Q30429980-A237BE3E-751E-4487-A84E-FD8E5FC2A965 Q35014605-AB7ED9A9-436D-420C-BE11-261EF77FC6C6 Q35093008-B1021506-EAB6-4324-9E7C-2366FBACFC60 Q35123675-DEB37021-B996-4EED-B042-B1CE76652FCB Q35412507-5280D8DE-443F-409B-B21D-9E2FD0C5F064 Q35533008-5C838479-50CD-404D-97CD-8ECCFAE203ED Q35676912-7532087B-8972-43C3-B504-9469DC9F1765 Q35732676-87105565-FF75-4CD3-A168-5348DD96B831 Q36083412-7F915182-3CA0-4A0D-9474-60A9B6E94A68 Q36120601-9890D2D0-AA89-4773-8066-84A59CA4A823 Q37133785-01116211-A52E-4532-AA52-486779EEB569 Q37410202-38FA8BFC-87D8-4A24-80B3-6ED7C14EC39F Q37538412-4527AAA7-D9D3-485A-B34C-6A2AEB550DF4 Q37892336-C6D9ADDE-B99E-4E53-A9F9-94E24C8F6A21 Q37898899-DDCB7C4D-BBCB-4AA0-847E-1C2709643F65 Q37954724-A3344E82-FEBB-4BC9-85F8-B5A9234746FA Q38105550-5936B39E-D416-4EBE-8294-2C935F1D3048 Q38112038-343C5E0F-C9FB-46A2-8303-0F0C16AA71DE Q38176678-7BF741B9-13F9-4F17-B01F-C42E60E20ED0 Q38267984-D99D9FF3-D770-4D1E-B126-EACECF07AF2E Q38542993-A56FD238-633D-4DD0-90D3-131EFEAD5178 Q38612061-9FC54B41-CEEE-44F0-BDF6-9885537271E4 Q38969083-CC541617-A66F-402F-A92F-637EF172F1B2 Q39353707-2709DF1E-697F-4F16-8D6C-A8B827CEE1AD Q40102349-62C32948-2B63-45CA-8DE2-D02067A74C8A Q44652714-35E46B50-EB66-4CC5-922A-B826DD61CA51 Q46280877-D00911B9-C80A-4A78-BFDE-E051AEAAF815 Q47709142-1C178DD5-5DA9-48F0-962A-50FC2D5027E9 Q47748436-8327163B-FDEE-4D8B-A799-C699CB016AA1 Q49471057-F1F7DDEB-7F55-4DE5-AC62-908ED0EA7F92 Q51192671-BC738339-2020-4C8B-8AC6-E4D9C9B1DA3D Q52668831-CC86E2E6-A740-49C3-A2F5-0E768EF28B08 Q54625083-5034998D-6F77-4A92-81BF-448307546A8C Q54977617-CF77FAC4-7999-4650-8D69-0D5F14BE592C Q55545711-332D8780-48E9-4BC5-8823-54488F8D5C2E Q58797618-F497E7AE-0416-4A5D-84E2-641172C8DE7D Q59137680-CC61205F-A1FE-4982-A934-047C5A4ECAF6

P2860

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

http://www.wikidata.org/entity/Q43256381

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

@en

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

@nl

type

label

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

@en

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

@nl

prefLabel

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

@en

Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

@nl

P1433

Q43256381-4E65E3D2-C34D-40DB-8181-35000766CB47

P1476

Q43256381-B6F1193B-1F21-4723-9F00-1F800CCC9C44

P2093

Q43256381-1B00E6A5-D954-4FCC-AC50-1D2FF7EE47F1

Q43256381-5CF8FC95-FFFE-4BFB-BCFA-F8BEF6A0824F

Q43256381-60CF85D7-9903-4B0B-B95C-9D1754EB4877

Q43256381-9B77BF2C-56D9-40C3-B72A-60EF1DCAF0ED

Q43256381-BD00352A-15B1-4A24-89DD-4E9CFC14F537

Q43256381-C3031D70-FFDC-4150-A10B-1B9DE0F821F6

Q43256381-F9D3386F-7586-4132-BA59-F03F78FBE3D2

P2860

Q43256381-0048B71A-A424-4347-80DF-CD6F52368D72

Q43256381-02A6C0B5-5362-48CD-8538-D6022D6646B4

Q43256381-0561BADB-0493-4070-AE21-6BC225BE9A09

Q43256381-0D95D91B-426A-44FE-909C-5A11C0BA7441

Q43256381-10E1B89B-EC4B-4DA7-BB01-57ABBB1E805C

Q43256381-12675162-7DC1-4112-906B-46DB54B8CA00

Q43256381-15ADAB1E-F2D4-4316-B393-73752583617E

Q43256381-182467E8-FFE6-487C-97CD-6160DEB282E2

Q43256381-216F5F20-5AA0-47BD-88F9-A6DFA7FD3C74

Q43256381-2832ED2E-DE26-4F9F-91D9-5B2B308E9099

P304

Q43256381-1C87B51A-1E3D-4AFC-8A17-536F5AE59A14

P31

Q43256381-6033CA5D-1879-41CD-B261-52C5A3746235

P356

Q43256381-5607CC1B-FC51-45DD-B596-4D69F6EA8217

P407

Q43256381-1EDD15F7-5C2A-468B-A0A6-35E54281184A

P433

Q43256381-7D730CF3-D456-4ABE-A49B-28E2C798FB0F

P478

Q43256381-B923BF74-01A9-4E29-86AE-37092F932667

P50

Q43256381-0C2DB0DF-D7D5-45CD-85B3-01D37396BAED

Q43256381-4E0EC505-AA07-4160-875C-CF85AAE36305

Q43256381-A35B550B-0660-483F-9D17-1D846A8FA841

Q43256381-B60ECC47-CB04-4DE7-8E11-77FDE5F7386A

Q43256381-C364CD8A-B06E-47CE-B5E8-098B9C56FACE

Q43256381-CF6931DD-13D5-4BEF-B12E-0CA8DBF7CA66

P577

Q43256381-4CEE1C0B-9926-4D0B-AB8D-7F684089209C

P5875

Q43256381-9714B3DE-F253-41D2-8509-BFD930E6AA9F

P698

Q43256381-5E6AB4A4-B2A8-43A1-9746-07CDCB35248B

P356

RCCM.200811-1682OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Role of epidermal growth factor inhibition in experimental pulmonary hypertension

@en

P2093

Aleksandra Tretyn

http://www.w3.org/2001/XMLSchema#string

Bhola Kumar Dahal

http://www.w3.org/2001/XMLSchema#string

Djuro Kosanovic

http://www.w3.org/2001/XMLSchema#string

Gamal-Andre Banat

http://www.w3.org/2001/XMLSchema#string

Rio Dumitrascu

http://www.w3.org/2001/XMLSchema#string

Robert Voswinckel

http://www.w3.org/2001/XMLSchema#string

Teodora Cornitescu

http://www.w3.org/2001/XMLSchema#string

P2860

ErbB receptors: from oncogenes to targeted cancer therapies

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma

Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src

A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling

Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.

Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes.

Reversal of experimental pulmonary hypertension by PDGF inhibition.

The epidermal growth factor receptor family: biology driving targeted therapeutics.

Treatment of pulmonary arterial hypertension.

P304

158-167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200811-1682OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

181

http://www.w3.org/2001/XMLSchema#string

P50

Friedrich Grimminger

Ardeschir Ghofrani

Ralph T Schermuly

Soni Savai Pullamsetti

Norbert Weissmann

P577

2009-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38030516

http://www.w3.org/2001/XMLSchema#string

P698

19850946

http://www.w3.org/2001/XMLSchema#string